FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889969172> ?p ?o ?g. }

• W2889969172 endingPage "76" @default.
• W2889969172 startingPage "1" @default.
• W2889969172 abstract "Background Two antiplatelet agents are better than one for preventing recurrent stroke after acute ischaemic stroke or transient ischaemic attack (TIA). Therefore, intensive treatment with three agents might be better still, providing it does not cause undue bleeding. Objective To compare the safety and efficacy of intensive therapy with guideline antiplatelet therapy for acute ischaemic stroke and TIA. Design International prospective randomised open-label blinded end-point parallel-group superiority clinical trial. Setting Acute hospitals at 106 sites in four countries. Participants Patients > 50 years of age with acute non-cardioembolic ischaemic stroke or TIA within 48 hours of ictus (stroke). Interventions Participants were allocated at random by computer to 1 month of intensive (combined aspirin, clopidogrel and dipyridamole) or guideline (combined aspirin and dipyridamole, or clopidogrel alone) antiplatelet agents, and followed for 90 days. Main outcome measures The primary outcome was the incidence and severity of any recurrent stroke (ischaemic, haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days by blinded telephone follow-up. Analysis using ordinal logistic regression was by intention to treat. Other outcomes included bleeding and its severity, death, myocardial infarction (MI), disability, mood, cognition and quality of life. Results The trial was stopped early on the recommendation of the Data Monitoring Committee after recruitment of 3096 participants (intensive, n = 1556; guideline, n = 1540) from 106 hospitals in four countries between April 2009 and March 2016. The incidence and severity of recurrent stroke or TIA did not differ between intensive and guideline therapy in 3070 (99.2%) participants with data [93 vs. 105 stroke/TIA events; adjusted common odds ratio 0.90, 95% confidence interval (CI) 0.67 to 1.20; p = 0.47]. Major (encompassing fatal) bleeding was increased with intensive as compared with guideline therapy [39 vs. 17 participants; adjusted hazard ratio (aHR) 2.23, 95% CI 1.25 to 3.96; p = 0.006]. There were no differences between the treatment groups in all-cause mortality, or the composite of death, stroke, MI and major bleeding (aHR 1.02, 95% CI 0.77 to 1.35; p = 0.88). Limitations Patients and investigators were not blinded to treatment. The comparator group comprised two guideline strategies because of changes in national guidelines during the trial. The trial was stopped early, thereby reducing its statistical power. Conclusions The use of three antiplatelet agents is associated with increased bleeding without any significant reduction in recurrence of stroke or TIA. Future work The safety and efficacy of dual antiplatelet therapy (combined aspirin and clopidogrel) versus aspirin remains to be defined. Further research is required on identifying individual patient response to antiplatelets, and the relationship between response and the subsequent risks of vascular recurrent events and bleeding complications. Trial registration Current Controlled Trials ISRCTN47823388. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 22, No. 48. See the NIHR Journal Library website for further project information. The Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) vanguard phase was funded by the British Heart Foundation (grant PG/08/083/25779, from 1 April 2009 to 30 September 2012) and indirect funding was provided by the Stroke Association through its funding of the Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK. There was no commercial support for the trial and antiplatelet drugs were sourced locally at each site. The trial was sponsored by the University of Nottingham." @default.
• W2889969172 created "2018-09-27" @default.
• W2889969172 creator A5013869274 @default.
• W2889969172 creator A5014786882 @default.
• W2889969172 creator A5018252886 @default.
• W2889969172 creator A5020407655 @default.
• W2889969172 creator A5023436129 @default.
• W2889969172 creator A5026156735 @default.
• W2889969172 creator A5026526616 @default.
• W2889969172 creator A5032240771 @default.
• W2889969172 creator A5032473948 @default.
• W2889969172 creator A5043655753 @default.
• W2889969172 creator A5045343269 @default.
• W2889969172 creator A5046999262 @default.
• W2889969172 creator A5053823041 @default.
• W2889969172 creator A5056101804 @default.
• W2889969172 creator A5056940847 @default.
• W2889969172 creator A5057794391 @default.
• W2889969172 creator A5062746761 @default.
• W2889969172 creator A5067179548 @default.
• W2889969172 creator A5075715319 @default.
• W2889969172 creator A5076797873 @default.
• W2889969172 creator A5078222721 @default.
• W2889969172 creator A5079383025 @default.
• W2889969172 creator A5089627879 @default.
• W2889969172 date "2018-08-01" @default.
• W2889969172 modified "2023-10-03" @default.
• W2889969172 title "Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT" @default.
• W2889969172 cites W10734288 @default.
• W2889969172 cites W13456847 @default.
• W2889969172 cites W148053018 @default.
• W2889969172 cites W1498265361 @default.
• W2889969172 cites W1501120985 @default.
• W2889969172 cites W1546258268 @default.
• W2889969172 cites W1553345686 @default.
• W2889969172 cites W1592471891 @default.
• W2889969172 cites W1638325886 @default.
• W2889969172 cites W1739627328 @default.
• W2889969172 cites W186716551 @default.
• W2889969172 cites W191849520 @default.
• W2889969172 cites W1964850644 @default.
• W2889969172 cites W1969842109 @default.
• W2889969172 cites W1972084369 @default.
• W2889969172 cites W1973975979 @default.
• W2889969172 cites W1976919205 @default.
• W2889969172 cites W1980847715 @default.
• W2889969172 cites W1985847675 @default.
• W2889969172 cites W1991655882 @default.
• W2889969172 cites W1996134888 @default.
• W2889969172 cites W1996336451 @default.
• W2889969172 cites W1997088717 @default.
• W2889969172 cites W2010303986 @default.
• W2889969172 cites W2014425845 @default.
• W2889969172 cites W2016051204 @default.
• W2889969172 cites W2024352468 @default.
• W2889969172 cites W2026458612 @default.
• W2889969172 cites W2034036386 @default.
• W2889969172 cites W2040961609 @default.
• W2889969172 cites W2042679477 @default.
• W2889969172 cites W2045121863 @default.
• W2889969172 cites W2046744461 @default.
• W2889969172 cites W2049777870 @default.
• W2889969172 cites W2053379248 @default.
• W2889969172 cites W2053482242 @default.
• W2889969172 cites W2054690731 @default.
• W2889969172 cites W2055623586 @default.
• W2889969172 cites W2055736359 @default.
• W2889969172 cites W2062028629 @default.
• W2889969172 cites W2071343574 @default.
• W2889969172 cites W2071686284 @default.
• W2889969172 cites W2073342193 @default.
• W2889969172 cites W2074204558 @default.
• W2889969172 cites W2078103827 @default.
• W2889969172 cites W2081615170 @default.
• W2889969172 cites W2081698307 @default.
• W2889969172 cites W2087387256 @default.
• W2889969172 cites W2091896847 @default.
• W2889969172 cites W2100209149 @default.
• W2889969172 cites W2106435303 @default.
• W2889969172 cites W2115803038 @default.
• W2889969172 cites W2115836576 @default.
• W2889969172 cites W2117029772 @default.
• W2889969172 cites W2118663843 @default.
• W2889969172 cites W2120531185 @default.
• W2889969172 cites W2120544643 @default.
• W2889969172 cites W2120859272 @default.
• W2889969172 cites W2121880538 @default.
• W2889969172 cites W2122223257 @default.
• W2889969172 cites W2126473393 @default.
• W2889969172 cites W2127272421 @default.
• W2889969172 cites W2130234815 @default.
• W2889969172 cites W2131454021 @default.
• W2889969172 cites W2132247347 @default.
• W2889969172 cites W2138595885 @default.
• W2889969172 cites W2140906876 @default.
• W2889969172 cites W2141472948 @default.
• W2889969172 cites W2142030374 @default.
• W2889969172 cites W2142765644 @default.

• next